Top-News
Pharmazeutika Schweiz

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF
267,30 $
+5,53 $
+2,11%
31.05.24 16:36:42
Handeln Depot/Watchlist
Aktienanzahl *
106,69 Mio.
Marktkapitalisierung *
27,27 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 11.12.2023

Roche Holding News

29.05.24 - GlobeNewswire
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Priority Review recognises the best-​in-class potential of the inavolisib-​based regimen for patients in urgent need of new treatment options 1,2 Additional analyses of INAVO120 will ...
27.05.24 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with ...
27.05.24 - GlobeNewswire
Wechsel in der erweiterten Konzernleitung von Roche
Basel, 27. Mai 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) gab heute bekannt, dass James Sabry (1958), M.D. Ph.D. und Leiter von Roche Pharma Partnering, nach vierzehn ...
22.05.24 - GlobeNewswire
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke. 1 The ...
21.05.24 - GlobeNewswire
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
The designation is based on Phase III INAVO120 results, showing the inavolisib-​based regimen more than doubled progression-​free survival compared with palbociclib and ...
16.05.24 - Der Aktionär
Roche: Adipositas‑Hoffnungsträger überzeugt – Fingerzeig in Richtung Novo Nordisk und Co
16.05.24 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
Over 24 weeks, a once-​weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-​adjusted weight loss of 18.8% (p At ...
15.05.24 - GlobeNewswire
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
More than half of all U.S. cervical cancer patients are underscreened 1 , which makes reducing barriers to sample collection and increasing access to screenings crucial to ...
24.04.24 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2% 1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, ...
24.04.24 - GlobeNewswire
[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte
Konzernverkäufe stiegen um 2% 1 zu konstanten Wechselkursen (CER; -6% in CHF) dank starkem Wachstum der jüngeren Medikamente und Diagnostika; ohne COVID-19-...
19.04.24 - GlobeNewswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-​positive early-​stage ...
17.04.24 - GlobeNewswire
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-​complete suppression of relapse activity (97%) ...
15.04.24 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell ...
11.04.24 - GlobeNewswire
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
The Elecsys® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and Company Once approved, the test will aid ...
26.03.24 - GlobeNewswire
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
The cobas Malaria test is the first FDA-​approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal parasitic infection most commonly ...
12.03.24 - GlobeNewswire
Roche Annual General Meeting 2024
All proposals of the Board of Directors approved Severin Schwan re-​elected as Chairman of the Board of Directors; all other Board members standing for election confirmed 37th ...
12.03.24 - GlobeNewswire
Roche Generalversammlung 2024
Alle Anträge des Verwaltungsrates genehmigt Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und ...
05.03.24 - GlobeNewswire
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a ...
25.02.24 - GlobeNewswire
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-​sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as ...
16.02.24 - GlobeNewswire
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-​sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with ...

Newssuche

Videos

newspaper
29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »